Midnight MarketsV1.0
⚠ Not financial adviceNot financial advice. Independent research, not investment recommendations. The author and website make no representation as to accuracy or completeness. Do your own due diligence before acting on anything you read here. Read the full disclaimer →
The Obesity Drugs — GLP-1 Duopoly · The GLP-1 & Bio Supply Chain — Peptides, Bioprocessing & Diagnostics

NVO

Novo Nordisk
loading…
History0 bars

Wegovy/Ozempic — the other half of the duopoly

What they do

Danish pharma company with Ozempic (diabetes) and Wegovy (obesity) — semaglutide compound. Plus Saxenda (older obesity drug) and a deep diabetes franchise. Lost the lead to Lilly in 2024-25 in both weight-loss efficacy and prescription growth. Pipeline: amycretin (oral GLP-1+amylin combo, Phase 2 data strong), CagriSema (next-gen obesity, Phase 3 disappointment 2024).